Precision-Engineered Cas12a: Eliminating Collateral DNA Cleavage for Next-Generation Genome Editing

Patent Status

Brief Description

CRISPR-Cas12a is a powerful genome-editing tool with broad applications across human therapeutics, agriculture, and biotechnology. However, naturally occurring Cas12a enzymes exhibit an additional, nonspecific single-stranded DNA (ssDNA) cleavage activity that may introduce unwanted DNA damage and compromise editing specificity.

Researchers in Jennifer Doudna's lab have engineered novel Cas12a variants that eliminate or substantially reduce this collateral ssDNA cleavage activity while preserving targeted double-stranded DNA (dsDNA) cutting. By modifying a short amino acid sequence, these engineered enzymes address a key limitation of conventional Cas12a systems.

The resulting variants offer the potential for more precise and controlled genome editing, reducing unintended DNA cleavage while retaining the core functionality of the CRISPR-Cas12a system. Compatible with applications in human, animal, and plant cells, this technology provides an opportunity to advance next-generation genome-editing tools with improved specificity and safety profiles.

By uncoupling targeted genome editing from unwanted collateral DNA cleavage, this innovation has the potential to make CRISPR-Cas12a a more precise and versatile platform for genetic engineering and therapeutic development.

Suggested uses

Genome editing in animals, plants, and human cells with: 

• Precision without collateral cleavage: Retains targeted editing while eliminating an unwanted enzymatic activity.
• Improved safety potential: Addresses a source of unintended DNA damage that is intrinsic to natural Cas12a enzymes.
• Platform compatibility: Improves an established CRISPR technology rather than requiring an entirely new genome-editing approach.

Advantages

Compared with conventional Cas12a and other CRISPR editing systems:

• Reduced collateral DNA damage: Eliminates or reduces nonspecific ssDNA cleavage while preserving targeted dsDNA cutting.
• Improved editing specificity: Potentially reduces unintended DNA damage associated with collateral nuclease activity.
• Preserved editing functionality: Maintains the core RNA-guided genome-editing capability of Cas12a.
• Engineered enzyme design: A relatively small protein modification may deliver a meaningful functional improvement without requiring an entirely new editing platform.
• Broad applicability: Potential use across human, animal, and plant genome-editing applications.
• Therapeutic development potential: May help address an important safety consideration in developing CRISPR-based genetic medicines.